Stocks and Investing
Stocks and Investing
Fri, February 16, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Salveen Richter Maintained (ADPT) at Hold with Decreased Target to $5 on, Feb 16th, 2024
Salveen Richter of Goldman Sachs, Maintained "Adaptive Biotechnologies Corporation" (ADPT) at Hold with Decreased Target from $11 to $5 on, Feb 16th, 2024.
Salveen has made no other calls on ADPT in the last 4 months.
There are 3 other peers that have a rating on ADPT. Out of the 3 peers that are also analyzing ADPT, 1 agrees with Salveen's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tejas Savant of "Morgan Stanley" Maintained at Hold with Decreased Target to $10 on, Tuesday, October 24th, 2023
These are the ratings of the 2 analyists that currently disagree with Salveen
- Rachel Vatnsdal of "JP Morgan" Maintained at Buy with Decreased Target to $8 on, Thursday, February 15th, 2024
- David Westenberg of "Piper Sandler" Maintained at Buy with Decreased Target to $6 on, Monday, November 13th, 2023
Contributing Sources